Table 2. Pregnancy Exposure to Modafinil and Armodafinil, 2010-2019.
| Characteristic | No. (%) | ||
|---|---|---|---|
| Prospective | Retrospective | Total | |
| Pregnancies (by individual) | |||
| Total No. | 122 | 26 | 148 |
| Lost to follow-up | 4 (3) | 0 | 4 (3) |
| Pregnancies complete (known outcomes) | 110 (90) | 26 (100) | 136 (92) |
| Outcome pending | 8 (7) | 0 | 8 (5) |
| Pregnancies with known outcomes (by fetus)a | |||
| Total No. | 116 | 26 | 142 |
| Live birth | 102 (88) | 17 (65) | 119 (84) |
| Major congenital malformationsb | 13 (13) | 3 (18) | 16 (13) |
| Spontaneous abortion | 13 (11) | 8 (31) | 21 (15) |
| Elective terminationc | 1 (1) | 1 (4) | 2 (1) |
| Fetal death | 0 | 0 | 0 |
a
Including 6 twin fetuses.
b
Percentage is calculated of total live births.
c
Termination in prospective case was because of diagnosis of trisomy 21 and in retrospective case because of unknown reasons.